KR20040004642A - 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도 - Google Patents

세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도 Download PDF

Info

Publication number
KR20040004642A
KR20040004642A KR10-2003-7015240A KR20037015240A KR20040004642A KR 20040004642 A KR20040004642 A KR 20040004642A KR 20037015240 A KR20037015240 A KR 20037015240A KR 20040004642 A KR20040004642 A KR 20040004642A
Authority
KR
South Korea
Prior art keywords
therapeutic
seq
arg
ser
leu
Prior art date
Application number
KR10-2003-7015240A
Other languages
English (en)
Korean (ko)
Inventor
메디슨에드윈엘
셈플죠셉에드워드
블라수크죠지피
켐프스코트제프리
코만들라말라레디
시브다니엘바나
Original Assignee
덴드레온 샌 디에고 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 덴드레온 샌 디에고 엘엘씨 filed Critical 덴드레온 샌 디에고 엘엘씨
Publication of KR20040004642A publication Critical patent/KR20040004642A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
KR10-2003-7015240A 2001-05-23 2002-05-23 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도 KR20040004642A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29326701P 2001-05-23 2001-05-23
US60/293,267 2001-05-23
PCT/US2002/016819 WO2002095007A2 (fr) 2001-05-23 2002-05-23 Conjugues actives par des proteases de surface cellulaire et leurs utilisations therapeutiques

Publications (1)

Publication Number Publication Date
KR20040004642A true KR20040004642A (ko) 2004-01-13

Family

ID=23128397

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-2003-7015240A KR20040004642A (ko) 2001-05-23 2002-05-23 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도

Country Status (5)

Country Link
EP (1) EP1545572A4 (fr)
JP (1) JP2005518332A (fr)
KR (1) KR20040004642A (fr)
CA (1) CA2447023A1 (fr)
WO (1) WO2002095007A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9869021B2 (en) 2010-05-25 2018-01-16 Aventa Technologies, Inc. Showerhead apparatus for a linear batch chemical vapor deposition system

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037667B1 (en) 1998-06-01 2006-05-02 Agensys, Inc. Tumor antigen useful in diagnosis and therapy of prostate and colon cancer
EP1544304A4 (fr) * 2002-07-31 2006-05-10 Astellas Pharma Inc Serine protease
JP5335191B2 (ja) 2003-08-22 2013-11-06 デンドレオン コーポレイション Ｔｒｐ−ｐ８発現に関連する疾患の処置をするための組成物および方法
EP1831370A4 (fr) 2004-12-13 2009-08-12 Alethia Biotherapeutics Inc Sequences polynucleotidiques et polypeptidiques participant au remodelage osseux
KR101393946B1 (ko) 2005-10-21 2014-05-12 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
US7772266B2 (en) 2006-02-15 2010-08-10 Dendreon Corporation Small-molecule modulators of TRP-P8 activity
CN101420942B (zh) 2006-02-15 2014-03-12 登德雷恩股份有限公司 Trp-p8活性的小分子调节剂
KR100906145B1 (ko) * 2006-05-30 2009-07-03 한국생명공학연구원 Ｔｍｐｒｓｓ4 억제제를 유효성분으로 포함하는 항암제
KR101778174B1 (ko) 2006-07-05 2017-09-13 카탈리스트 바이오사이언시즈, 인코포레이티드 프로테아제 스크리닝 방법 및 이에 의해 확인된 프로테아제
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
TWI465247B (zh) 2008-04-11 2014-12-21 Catalyst Biosciences Inc 經修飾的因子ｖｉｉ多肽和其用途
EP2353609A1 (fr) 2010-02-04 2011-08-10 Sanofi Pasteur Compositions et procédés d'immunisation
CN103069555B (zh) 2010-08-18 2016-10-26 独立行政法人产业技术综合研究所 有机半导体薄膜以及有机半导体单晶薄膜的制造方法
EP2814807A4 (fr) * 2012-02-16 2015-10-07 Rqx Pharmaceuticals Inc Antibiotiques à peptide linéaire
SG11201500412TA (en) 2012-07-24 2015-02-27 Sanofi Pasteur Vaccine compositions
US20150265695A1 (en) 2012-07-24 2015-09-24 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
MX365612B (es) 2012-07-25 2019-06-07 Catalyst Biosciences Inc Polipeptidos de factor x modificados y usos de los mismos.
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
RU2737434C2 (ru) 2013-03-13 2020-11-30 Форма Терапьютикс, Инк. Новые соединения и композиции для ингибирования fasn
AU2017273857B2 (en) 2016-06-01 2021-08-19 Athira Pharma, Inc. Compounds
US10781435B2 (en) 2017-06-22 2020-09-22 Catalyst Biosciences, Inc. Modified membrane type serine protease 1 (MTSP-1) polypeptides and methods of use
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
US20210069306A1 (en) 2019-08-15 2021-03-11 Catalyst Biosciences, Inc. Modified factor vii polypeptides for subcutaneous administration and on-demand treatment
EP3932935A1 (fr) * 2020-06-29 2022-01-05 Centre National de la Recherche Scientifique Peptides antibactériens

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5972616A (en) * 1998-02-20 1999-10-26 The Board Of Trustees Of The University Of Arkansas TADG-15: an extracellular serine protease overexpressed in breast and ovarian carcinomas
EP1161266A4 (fr) * 1999-03-12 2007-09-19 Univ Georgetown Matriptase, protease de la serine, et son utilisation
WO2001036604A2 (fr) * 1999-11-18 2001-05-25 Corvas International, Inc. Acides nucleiques codant pour des endotheliases, endotheliases et leurs utilisations
EP1263473A2 (fr) * 2000-03-15 2002-12-11 Bristol-Myers Squibb Pharma Company Medicaments antineoplastiques cibles pouvant etre clives par la peptidase et utilisation therapeutique de ces medicaments
CA2451188A1 (fr) * 2001-06-25 2003-01-03 Drug Innovation & Design, Incorporated Ciblage cellulaire faisant appel a la reconnaissance des formes exponentielle, compositions, procedes et applications anticancereuses
WO2003037326A1 (fr) * 2001-10-29 2003-05-08 Corvas International, Inc. Synthese en phase solide de chimiotheques
JP2006503545A (ja) * 2002-02-14 2006-02-02 ラター， ウィリアム ジェイ． 処置される宿主における切断についてのキメラ分子
AU2003269880A1 (en) * 2002-05-21 2003-12-22 Dendreon Corporation Nucleic acid molecules encoding a transmembrane serine protease 12, the encoded polypeptides and methods based thereon

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9869021B2 (en) 2010-05-25 2018-01-16 Aventa Technologies, Inc. Showerhead apparatus for a linear batch chemical vapor deposition system

Also Published As

Publication number Publication date
EP1545572A2 (fr) 2005-06-29
JP2005518332A (ja) 2005-06-23
WO2002095007A2 (fr) 2002-11-28
WO2002095007A3 (fr) 2005-05-06
CA2447023A1 (fr) 2002-11-28
EP1545572A4 (fr) 2006-04-12

Similar Documents

Publication Publication Date Title
KR20040004642A (ko) 세포 표면 프로테아제에 의해 활성화되는 접합체 및 이의치료학적 용도
US20040001801A1 (en) Conjugates activated by cell surface proteases and therapeutic uses thereof
US9775913B2 (en) Method of site specific activation of an antibody by a protease
JP3481948B2 (ja) 新規ペプチド
EP1144011B1 (fr) Composes de promedicaments et procede de preparation
US5948750A (en) Conjugates useful in the treatment of prostate cancer
ES2364452T3 (es) Método para diseñar compuestos profármacos activados por cd10.
JP3607201B2 (ja) Ｆａｐ活性化抗腫瘍性化合物
US6391305B1 (en) Conjugates useful in the treatment of prostate cancer
AU726434B2 (en) Conjugates useful in the treatment of prostate cancer
JP2003526683A (ja) ペプチダーゼ切断可能な標的抗新生物薬およびそれらの治療への使用
US20070021350A1 (en) Conjugates useful in the treatment of prostate cancer
US5998362A (en) Conjugates useful in the treatment of prostate cancer
AU708475B2 (en) Conjugates useful in the treatment of benign prostatic hyperplasia
US6174858B1 (en) Conjugates useful in the treatment of prostate cancer
US20030232760A1 (en) Conjugates useful in the treatment of prostate cancer
US20070129309A1 (en) Conjugates useful in the treatment of prostate cancer
US20030133927A1 (en) Conjugates useful in the treatment of prostate cancer
US20020115596A1 (en) Conjugates useful in the treatment of prostate cancer
KR102436012B1 (ko) 항암제 프로드러그 컨쥬게이트의 새로운 용도
US20050119166A1 (en) Conjugates useful in the treatment of prostate cancer
US20190015519A1 (en) Mmp-sensitive taxane prodrug
AU2002312119A1 (en) Conjugates activated by cell surface proteases and therapeutic uses thereof
AU714288B2 (en) Novel peptides
US20020173451A1 (en) Method of treating cancer

Legal Events

Date Code Title Description
N231 Notification of change of applicant
WITN Withdrawal due to no request for examination